Procter & Gamble wins patent suit for Actonel
CINCINNATI The United States District Court of Delaware today ruled in favor of the Procter & Gamble Company in the patent infringement lawsuit filed by P&G against Teva Pharmaceuticals. The positive ruling protects P&G’s rights in the U.S. to exclusively market the osteoporosis therapy Actonel (risedronate sodium tablets).
P&G filed a patent infringement lawsuit in August against Teva to enforce P&G’s U.S. composition of matter patent for risedronate, the active ingredient in Actonel. Teva was seeking to market a generic version of Actonel in the United States under the assertion that the Actonel patent was not valid due to obviousness of the invention.
The court ruled today in favor of the patent. “We are pleased that the Court recognized and acknowledged the uniqueness of the risedronate molecule,” said Tom Finn, P&G president of global health care. “We are very proud of the extensive R&D efforts which brought Actonel to market, providing patients help that they need to manage their osteoporosis and prevent fractures.”
Mylan contemplates selling Dey due to Q3 loss
PITTSBURGH Mylan, a generic drug maker, has experienced a fiscal third-quarter-loss due to the $1.27 billion write off of acquired research and development related to acquisitions.
Shares for the company fell $1.41, or 11 percent, to $11.74 during aftermarket electronic trading, after closing down 12 cents at $13.15.
According to published reports, the loss for the quarter ended Dec. 31 totaled $1.38 billion. The company is said to possibly sell specialty business Dey LP. Selling Dey; however, will delay the launch of Perforomist, a treatment for emphysema and chronic bronchitis. This delay is predicted to hurt their earnings by 20 to 25 cents per share in 2008 to 2010.
The company is also planning to discontinue manufacturing and research at its facility in Canada, and stop manufacturing products in Puerto Rico. According to published reports, it will also stop research and development at Gerard Laboratories in Ireland and Spain.
Federal advisory panel recommends flu shot be given to all children
ATLANTA A federal advisory panel said Wednesday that all children up to age 18 should get vaccinated against the flu. The only exception was children under six months and those that have serious egg allergies.
Flu shots have usually been recommended to those that are at the highest risk of detrimental effects from the flu, such as children ages 6 months to 5 years, adults 50 and older, and those that have a weak immune system. This year, however, experts suggest that a way to prevent those at risk from being infected, all children, very effective carriers of the influenza virus, should be inoculated.
According to published reports, the Advisory Committee on Immunization Practices says this year that all children should get vaccinated as soon as possible. Offering flu shots to all children would add about 30 million more children than usual. FluMist, a nasal spray vaccine is also approved for ages 2 to 49, as an alternative to the shot.
The new advisory for flu shots has caused arguments among doctors as to when the vaccines should be available. Some doctors feel that the vaccine should be offered universally, while others are unsure of how every child will get covered with the vaccine.
“We probably will need to have low expectations for coverage in the first few years of implementation” of the ages 5-through-18 recommendation, said Tony Fiore, an epidemiologist with the Centers for Disease Conrol and Prevention.